CA2804165C - Piperidinyl pyrimidine amides as kv7 potassium channel openers - Google Patents

Piperidinyl pyrimidine amides as kv7 potassium channel openers Download PDF

Info

Publication number
CA2804165C
CA2804165C CA2804165A CA2804165A CA2804165C CA 2804165 C CA2804165 C CA 2804165C CA 2804165 A CA2804165 A CA 2804165A CA 2804165 A CA2804165 A CA 2804165A CA 2804165 C CA2804165 C CA 2804165C
Authority
CA
Canada
Prior art keywords
disorder
depression
treatment
disease
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2804165A
Other languages
English (en)
French (fr)
Other versions
CA2804165A1 (en
Inventor
Michelle Marie Claffey
Jennifer Elizabeth Davoren
John Adams Lowe, Iii
Robert Joseph Mather
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA2804165A1 publication Critical patent/CA2804165A1/en
Application granted granted Critical
Publication of CA2804165C publication Critical patent/CA2804165C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2804165A 2010-07-08 2011-06-20 Piperidinyl pyrimidine amides as kv7 potassium channel openers Expired - Fee Related CA2804165C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36250510P 2010-07-08 2010-07-08
US61/362,505 2010-07-08
PCT/IB2011/052686 WO2012004698A1 (en) 2010-07-08 2011-06-20 Piperidinyl pyrimidine amides as kv7 potassium channel openers

Publications (2)

Publication Number Publication Date
CA2804165A1 CA2804165A1 (en) 2012-01-12
CA2804165C true CA2804165C (en) 2015-02-24

Family

ID=44487037

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2804165A Expired - Fee Related CA2804165C (en) 2010-07-08 2011-06-20 Piperidinyl pyrimidine amides as kv7 potassium channel openers

Country Status (11)

Country Link
US (1) US8883812B2 (https=)
EP (1) EP2590961A1 (https=)
JP (1) JP5763758B2 (https=)
KR (1) KR101449348B1 (https=)
CN (1) CN102971307A (https=)
AU (1) AU2011275393B2 (https=)
CA (1) CA2804165C (https=)
MX (1) MX2013000138A (https=)
SG (1) SG186409A1 (https=)
WO (1) WO2012004698A1 (https=)
ZA (1) ZA201300499B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013067591A1 (en) * 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014145852A2 (en) 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
SMT202300362T1 (it) * 2014-09-12 2023-11-13 Biohaven Therapeutics Ltd Benzoimidazol-1,2-il-ammidi come attivatori di canale kv7
EP4241843B1 (en) * 2018-02-20 2025-05-21 H. Lundbeck A/S Alcohol derivatives as kv7 potassium channel openers
SG11202008030WA (en) 2018-03-19 2020-10-29 Knopp Biosciences Llc Kv7 channel activators compositions and methods of use
AR119521A1 (es) * 2019-08-02 2021-12-22 H Lundbeck As DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7
BR112022004847A2 (pt) * 2019-09-17 2022-06-07 Knopp Biosciences Llc Método para tratar uma doença ou distúrbio de neurodesenvolvimento
WO2021119018A1 (en) * 2019-12-09 2021-06-17 The Board Of Trustees Of The Leland Stanford Junior University A method to improve sleep quality in the elderly by controlling excitability of hypocretin neurons
WO2021211867A1 (en) * 2020-04-16 2021-10-21 Attune Neurosciences, Inc. Kv7 modulators for treating sleep or anxiety disorders
BR112023003624A2 (pt) * 2020-08-28 2023-03-28 Pfizer Ferramenta de suporte à decisão computadorizada e dispositivo médico para monitoramento e cuidado de condição respiratória
GB202306914D0 (en) * 2023-05-10 2023-06-21 Sania Rx Ltd Method
CN119661413B (zh) * 2024-12-28 2025-06-24 齐鲁医药学院 Kv7钾离子通道开放剂及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20032233A3 (cs) * 2001-02-20 2004-12-15 Bristol-Myers Squibb Company Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
US7091202B2 (en) * 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
US20080261918A1 (en) 2004-12-17 2008-10-23 Graham Andrew Showell Silicon Compounds and Their Use
US7322249B2 (en) 2005-07-07 2008-01-29 Delphi Technologies, Inc. Mounting for a probe sensor
US7683058B2 (en) * 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
KR20080043314A (ko) * 2005-09-09 2008-05-16 하. 룬트벡 아크티에 셀스카브 피리미딘 유도체 및 ｋｃｎｑ 포타슘 채널 개방제로서의그의 용도
TWI453013B (zh) 2006-02-07 2014-09-21 Lundbeck & Co As H N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品
SG174095A1 (en) * 2006-08-23 2011-09-29 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
AR070513A1 (es) 2007-08-01 2010-04-14 Lundbeck & Co As H Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor

Also Published As

Publication number Publication date
ZA201300499B (en) 2013-09-25
KR101449348B1 (ko) 2014-10-08
AU2011275393B2 (en) 2014-04-10
US8883812B2 (en) 2014-11-11
SG186409A1 (en) 2013-02-28
US20130150391A1 (en) 2013-06-13
KR20130031323A (ko) 2013-03-28
WO2012004698A1 (en) 2012-01-12
JP5763758B2 (ja) 2015-08-12
EP2590961A1 (en) 2013-05-15
MX2013000138A (es) 2013-03-05
AU2011275393A1 (en) 2013-01-10
JP2013531006A (ja) 2013-08-01
CA2804165A1 (en) 2012-01-12
CN102971307A (zh) 2013-03-13

Similar Documents

Publication Publication Date Title
CA2804165C (en) Piperidinyl pyrimidine amides as kv7 potassium channel openers
EP3227271B1 (en) Heterocyclic derivatives and use thereof
EP3487839B1 (en) Amide derivatives as nav1.7 and nav1.8 blockers
AU2016223072B2 (en) Selective BACE1 inhibitors
JP7450559B2 (ja) 疾患の処置のためのｋｄｍ１ａ阻害剤
WO2020146612A1 (en) Esters and carbamates as modulators of sodium channels
EP3150592B1 (en) Alk kinase inhibitor, and preparation method and use thereof
AU2013259904A1 (en) Bicyclic sulfone compounds for inhibition of RORy activity and the treatment of disease
AU2020207162B2 (en) (2,5-Dioxopyrrolidin-1-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases
BRPI0911990A2 (pt) compostos de piridina prolinamida e seu uso na terapia
CA2792918A1 (en) Benzazepine compound
JP2023515101A (ja) 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法
CA3178647A1 (en) Substituted tricyclic amides, analogues thereof, and methods using same
CA2809217A1 (en) Pyrimidones for treatment of potassium channel related diseases
JP2021104931A (ja) 含窒素複素環を有するジベンゾアゼピン誘導体
AU2004289616B2 (en) Morpholine derivatives as norepinephrine reuptake inhibitors
AU2017268154B2 (en) N-[3-[2-Amino-5-(1,1-difluoroethyl)-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]oxazin-7a-yl]-4-fluoro-phenyl]-5-(trifluoromethyl)pyridine-2-carboxamide and its (4aR,5S,7aS) isomer as a selective BACE1 inhibitor for treating e.g. Alzheimer's disease
HK1177199A (en) Piperidinyl pyrimidine amides as kv7 potassium channel openers
JP2026509368A (ja) Ｔｄｐ－４３及びタウ凝集の阻害剤
EA041031B1 (ru) Дейтерированные пиридонамиды и их пролекарства в качестве модуляторов натриевых каналов

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20121231

MKLA Lapsed

Effective date: 20170620